Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein

September 22, 2016 3:40 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Rumors, Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment